Back to Search Start Over

[PI3K-AKT-mTOR pathway and cancer].

Authors :
Coutte L
Dreyer C
Sablin MP
Faivre S
Raymond E
Source :
Bulletin du cancer [Bull Cancer] 2012 Feb 01; Vol. 99 (2), pp. 173-80.
Publication Year :
2012

Abstract

PI3K/AKT/mTOR pathway is an intracellular signalling pathway composed of different kinases. Many protein mutations are described in that pathway, and are responsible of dysregulation of cell growth, proliferation, survival and angiogenesis. Rapamycin is an antibiotic inhibiting mTOR. Different analogs of rapamycin are developed or being developed in antitumoral therapy, in which temsirolimus, everolimus and deforolimus, demonstrated antitumoral activity in renal cancer and mantle cell lymphoma, and many clinical trials are in progress in other tumors. In the future, predictive factors of response need to be identified; patient selection and associations with chemotherapy or with other targeted therapies should be explored.

Details

Language :
French
ISSN :
1769-6917
Volume :
99
Issue :
2
Database :
MEDLINE
Journal :
Bulletin du cancer
Publication Type :
Academic Journal
Accession number :
21742593
Full Text :
https://doi.org/10.1684/bdc.2011.1384